The potential health impact and healthcare cost savings of different sodium reduction strategies in Canada

3

4 Nadia Flexner^{1*}, Amanda C. Jones², Ben Amies-Cull³, Linda Cobiac⁴, Eduardo Nilson^{5,6}, Mary
 5 R. L'Abbe^{1*}

5 6

¹Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto,

Toronto, Canada.

²Department of Public Health, University of Otago, Wellington, New Zealand.

³Nuffield Department of Primary Care Healthcare Sciences, University of Oxford, Oxford, United Kingdom.

⁴Griffith University, Queensland, Australia.

⁵Center for Epidemiological Research in Nutrition and Public Health, University of São Paulo, São Paulo, Brazil.

⁶Oswaldo Cruz Foundation (Fiocruz/Brasilia), Brasilia, Brazil.

*Corresponding authors: <u>mary.labbe@utoronto.ca; nadia.flexner@mail.utoronto.ca</u>

7 Keywords: sodium reduction, health impact, cardiovascular disease, cost-utility analysis, multi-

- 8 state lifetable model, food policy.
- 9

10 Abstract

11 Background

- 12 High dietary sodium is the main dietary risk factor for non-communicable diseases due to its
- 13 impact on cardiovascular diseases, the leading cause of death globally. The Government of
- 14 Canada has taken measures to reduce average dietary sodium intakes, such as setting voluntary
- sodium reduction targets for packaged foods and recently approving regulations mandating 'high
- 16 in' front-of-pack labeling (FOPL) symbols.

17 **Objectives**

18 To estimate the number of avoidable ischemic heart disease (IHD) and stroke incidence cases,

- 19 and their associated healthcare cost and Quality-Adjusted Life Year (QALY) savings resulting
- 20 from different sodium reduction strategies and recommendations in Canada.

21 Methods

We used the PRIMEtime model, a proportional multi-state lifetable model. Outcomes were modeled over the lifetime of the population alive in 2019, at a 1.5% discount rate, and from the public healthcare system perspective. Nationally representative data were used as inputs for the model.

26 **Results**

Fully meeting Health Canada's sodium reduction targets was estimated to prevent 219,490 (95%

28 UI, 73,409–408,630) cases of IHD, and 164,435 (95% UI, 56,121–305,770) strokes. This led to a

- 29 gain of 276,185 (95% UI, 85,414–552,616) QALYs, and healthcare costs savings of CAD\$
- 4,212(95% UI, 1,303–8,206) million over the lifetime of the 2019 cohort. Sodium reduction

intake through FOPL regulations has the potential to prevent between 35,930 (95% UI, 8,058–

- 32 80,528) and 124,744 (95% UI, 40,125–235,643) cases of IHD, and between 26,869 (95% UI,
- 33 5,235–61,621) and 93,129 (95% UI, 30,296–176,014) strokes. This results in QALY gains
- ranging from 45,492 (95% UI, 10,281–106,579) to 157,628 (95% UI, 46,701–320,622), and
- healthcare costs savings ranging from CAD\$ 695 (95% UI, 160–1,580) to CAD\$ 2,415 (95% UI,
- 36 722–4,746) million over the lifetime of the 2019 Canadian cohort. Greater health and healthcare
- 37 costs gains were estimated if Canadians were to meet the population-level sodium intake

38	recommendations of the World Health Organization (2,000 mg/day) and the Adequate Intake
39	recommendation (1,500 mg/day). All sodium reduction strategies tested were cost saving.
40	Conclusions
41	Reducing population-level sodium intakes is feasible and has the potential to improve health
42	outcomes and save healthcare costs in Canada. From interventions tested, most health and
43	healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights
44	the importance of changing the voluntary nature of these targets to mandatory. A combination of
45	strategies, mandatory sodium reduction targets and implementation of the 'high in' FOPL

46 symbol would provide the most benefit from a public health standpoint.

47 **1. Introduction**

48	Diets high in sodium are the main dietary risk factor for non-communicable diseases (NCDs)(1)
49	due to their impact on cardiovascular diseases (CVDs)(2, 3), the leading cause of death globally
50	and a major contributor to disability, particularly in relation to diseases such as ischemic heart
51	disease (IHD) and stroke(4). In Canada, CVDs (mostly IHD and strokes) rank as the second
52	leading cause of death (after cancers), accounting for 25% of all deaths each year(5). The World
53	Health Organization (WHO) broadly considers reducing population-level dietary sodium intake
54	to be a cost-effective measure that could save many lives by decreasing and preventing the
55	burden of diet-related NCDs, mainly from CVDs, and save costs in the long run(6, 7).
56	The WHO recommends consuming less than 2,000 mg/day of sodium (5 g/day of salt)(8);
57	however, intake levels around the world largely exceed recommendations(8). Canada is not an
58	exception, as recent sodium intake estimations showed that Canadians consume an average of
59	2,760 mg/day of sodium(9, 10), with 63.9% of Canadian adults exceeding the recommendation
60	for Chronic Disease Risk Reduction (CDRR) levels (2,300 mg/day) and only 9.4% of Canadian
61	adults meeting the Adequate Intake (AI) levels (1,500 mg/day) ¹⁰ .
62	Reducing sodium intake is a WHO 'best buy' recommendation for the prevention and control of
63	NCDs(6). In its SHAKE Technical Package for Salt Reduction(11), WHO recommends ideally
64	implementing a joint combination of measures to reduce population-level sodium intakes. These
65	measures include monitoring salt use (e.g., intakes, salt content in foods), promote food
66	reformulation to contain less salt by setting salt targets levels in foods, adopting interpretive
67	front-of-pack labeling systems, and restricting marketing of foods 'high in' salt, among

68 others(11).

4

69	The Canadian government has implemented and adopted several evidence-based policies to
70	make the healthier choice easier for all Canadians, as described in the Canadian Healthy Eating
71	Strategy (2016)(12). As part of this comprehensive strategy, Health Canada committed to
72	ongoing collaboration with stakeholders in the food industry to reduce sodium levels in packaged
73	foods through updating the voluntary sodium reduction targets for processed foods (2020-
74	2025)(13). It is worth noting that progress evaluations of the previous (2012-2016) set of
75	voluntary sodium reduction targets have only shown modest results(14), and only minor
76	revisions have been made to the latest set of targets (2020-2025)(13). In addition, Health Canada
77	recently approved front-of-pack labeling (FOPL) regulations that will require packaged foods
78	that meet or exceed established thresholds for nutrients-of-concern, including sodium, to display
79	a 'high in' FOPL nutrition symbol, to come into effect by January 2026(15).
80	Estimating the impact of public health polices, such as the aforementioned, could be challenging
81	or simply not feasible using traditional epidemiological research methods such as cohort studies,
82	randomized control trials or natural experiments. Policy scenario modeling has proven to be an
83	appropriate and strategic tool for estimating the health and economic impact of public health
84	policies prior to actual implementation(16). Specifically, NCD policy scenario modeling allows
85	us to predict the cumulative health outcomes of interventions over the long term and across the
86	entire population; in addition to providing evidence on what the magnitude would be to take
87	action or not by comparing different policy scenarios with a 'business as usual' scenario(17).
88	A systematic review of previous policy scenario modeling studies have demonstrated the cost-
89	effectiveness of reducing dietary sodium intake(18). Studies in the Canadian context have
90	estimated the economic and health impact of reducing sodium intake to recommended levels
91	when compared to previous sodium intake levels (i.e., 3,800 mg/day) using data from CCHS-

92	Nutrition 2004(19). More recently, using data from CCHS-Nutrition 2015, we previously
93	estimated the number of CVDs deaths that could be averted or delayed if Canadians were to
94	reduce their sodium intake to recommended levels(10, 19), and as a result of implementing 'high
95	in' FOPL regulations(20, 21). However, to the best of our knowledge, no study in Canada has
96	previously estimated the health impact and healthcare cost savings from 'real world' policy
97	scenario options to reduce population level dietary sodium intakes (i.e., food reformulation and
98	mandatory 'high in' FOPL symbol).

In this study, we aimed to provide policymakers and stakeholders with evidence supporting policy options to reduce excess dietary sodium intakes in Canada. We estimated the number of avoidable ischemic heart disease and stroke incidence cases, and their associated healthcare cost, and Quality-Adjusted Life Year (QALY) savings resulting from 1) meeting sodium intake recommended levels, 2) meeting sodium reduction targets for packaged foods established by Health Canada, and 3) implementing 'high in' front-of-pack labeling regulations in Canada.

2. Materials and methods

We conducted a cost-utility analysis using a public healthcare system perspective. The potential
health and healthcare costs impact of reducing dietary sodium intake were modelled by
comparing ten counterfactual scenarios (described below in section *'Counterfactual scenarios modeled'*) to a 'business as usual' or 'baseline' scenario. Outcomes were modeled over the
lifetime of the Canadian population alive in 2019, and a 1.5% discount rate was applied to both
health gains and healthcare costs, as recommended by the Canadian Agency for Drugs and
Technologies in Health (CADTH)(22).

113 *2.1 PRIMEtime model: a proportional multi-state lifetable model*

The PRIMEtime model, an established and robust proportional multi-state lifetable model, was 114 used in this study(23, 24). PRIMEtime is an epidemiological model tool, developed by 115 researchers at the University of Oxford, that has been widely applied to a range of different diet 116 117 and obesity policy scenarios in the UK and other countries (24-31). This model has been designed for policy scenario evaluation and can be utilized to assess future effects of policies in order to 118 help policymakers set priorities for action. In a world of limited resources, governments are 119 120 increasingly required to properly assess the cost-effectiveness of interventions to strategically allocate their resources. The PRIMEtime model is a tool for policy support and prioritization that 121 under the same set of assumptions can help compare different policy options by assessing the 122 cost-effectiveness of interventions. 123

124 The PRIMEtime model is comprised of the following interconnected modules: a risk factor 125 exposure module, a series of disease models, and a lifetable. Detailed methods of the model have 126 been published elsewhere(24). Briefly, PRIMEtime uses epidemiological data collected mainly from meta-analyses of randomized control trials or prospective cohort studies to parameterize the 127 128 relationships between risk factors and NCDs. This can be modeled as direct effects of risk factors or via their intermediate risk factors (i.e., blood pressure, BMI, or total cholesterol), where 129 appropriate. The Canadian PRIMEtime Salt model includes the two main CVDs associated with 130 high consumption of salt/sodium, IHD and stroke. These diseases are modeled in PRIMEtime in 131 a three-state Markov model in which the population is either in a disease-free state, a diseased 132 133 state, or dead. Then, the lifetable combines these simulated changes in population health and healthcare system as a result of changes in disease epidemiology. 134

7

We adapted the PRIMEtime model to the Canadian context by collecting, processing, and analyzing Canadian-specific and nationally representative data (i.e., dietary sodium intakes, population demographics, disease epidemiology and healthcare costs). **Table 1** shows the data sources used as inputs for the PRIMEtime model in Canada. A closed cohort analyses was performed, taking the Canadian adult population as a baseline (\geq 19 y) over the lifetime of the cohort or until they reach 100y of age.

141 2.2Model input parameters

142 *Population inputs*

Canadian population size and all-cause mortality data by 1-year age/sex groups were included in the model. Data was obtained from the publicly available Statistics Canada CANSIM tables for the year 2019 (**Table 1, Supplementary Table S1**). All-cause mortality data was only available in 5-year age/sex groups; thus, further processing was required. Data was interpolated to 1-year using a temporal disaggregation method(32).

148 *Disease epidemiology*

149 Data on incidence, prevalence and disease-specific mortality were collected for ischemic heart

disease and stroke for the year 2019 (Table 1). First, we prioritized alignment of WHO

151 International Statistical Classification of Diseases and Related Health Problems 10th Revision

152 (ICD-10) codes(33) between disease epidemiology and healthcare cost data (described below).

- 153 Disease epidemiology data was only available in 5y age/sex groups up to age 90+ for all
- parameters; thus, further processing was required. Data was extrapolated to age 100+ using a
- polynomial trend line (Supplementary Table S2). Then, health data estimates were interpolated

to 1y age/sex groups using a temporal disaggregation method to obtain smooth disaggregatedcounts, while maintaining the aggregated total(32).

Case fatality rates were derived from cause-specific incidence, prevalence and mortality data, together with population size using a Bayesian approach, the *disbayes* optimization method built on the Stan software (*disbayes* package available in R)(32, 34). It was assumed that case fatality was constant for all ages below 35. The *disbayes* package estimates case fatality using a threestate transition process of disease free, disease, or death. The *disbayes* ' approach and assumptions are consistent with the ones underpinning disease simulation in the PRIMEtime model (**Supplementary Table S1**).

165 Mean systolic blood pressure (SBP) estimates for the year 2019 were acquired. Data was

available by sex (male, female) and age group (6-11 years, 12-19, 20-39, 40-59, 60-79) (**Table**

167 1). As SBP measurements were not available for individuals aged 80 years and older, we

assumed the same values as those observed for 60-79 years age/sex groups for individuals in the
80+ years group.

170 *Dietary sodium intake*

This study used data from the Canadian Community Health Survey (CCHS)-Nutrition 2015 to estimate baseline and counterfactual dietary sodium intakes for Canadian adults (\geq 19 y). CCHS-Nutrition 2015 is a nationally representative, cross-sectional health and nutrition survey that utilized 24-hour (24h) dietary recalls to collect data on food and beverage intake across the 10 Provinces of Canada (aged 1y or older)(35). We used both available days of 24h dietary recalls to estimate usual dietary sodium intakes for adults by Dietary Reference Intakes (DRI)(36)

- age/sex groups (i.e., males and females ages 19-30, 31-50, 51-70, 71+), methods that have been
- 178 previously published by our research group(10, 20, 21).
- 179 Counterfactual scenarios modeled
- 180 *Meeting sodium intake recommended levels (Scenarios 1 and 2)*
- 181 We modeled potential health and healthcare costs gains from meeting WHO sodium intake
- recommendations of 2,000 mg/day and the AI recommendations of 1,500 mg/day. The
- 183 proportion needed to meet these recommendations from the current sodium intakes (2,758
- 184 mg/day) was calculated and applied to each DRI age/sex group to build our counterfactual
- 185 scenarios¹⁰ (**Table 2**, **Supplementary Table S3**).
- 186 *Meeting sodium reduction targets established by Health Canada (Scenario 3)*

Fully meeting Health Canada's voluntary sodium reduction targets for packaged foods was used 187 as one of the counterfactual scenarios tested in this study. Our research group has previously 188 published methods for this policy modeling approach(10, 37). Briefly, data from a Canadian 189 branded packaged food composition database, the University of Toronto's Food Label 190 Information and Price database (FLIP 2017), was linked to the Food and Ingredient Details (FID) 191 file in the CCHS-Nutrition 24-hour recall to estimate baseline and counterfactual dietary sodium 192 193 intakes. The counterfactual scenario was estimated after conducting a systematic 'reformulation' of eligible packaged foods to meet Health Canada's sodium reduction targets¹⁰ (Table 2, 194 Supplementary Table S3). 195

196 *Implementing 'high in' front-of-pack labeling regulations (Scenarios 4-10)*

Based on recent FOPL evidence from observational and experimental studies (38-40), we 197 estimated potential changes to dietary sodium intakes(20). These studies estimated changes in 198 199 the content of nutrients of public health concern (i.e., saturated fats, sodium, and sugars) in food and beverage purchases when a 'high in' FOPL was in place. We assumed that changes observed 200 in food and beverage purchases would carry over to dietary intakes, as evidence suggests that 201 202 documented food purchases can serve as a reasonably precise estimate of overall diet quality(41). 203 We modeled changes in overall food and beverage sodium content based on early evaluations of 204 the Chilean Food Labeling and Marketing Law (-4.7%)(38) (Scenario 4), the criteria used by 205 WHO to estimate FOPL cost-effectiveness as part of the Technical briefing for Appendix 3 of the Global Action Plan for NCDs (-6.4%)(40) (Scenario 5), and a FOPL systematic review and 206 network meta-analysis (-7.8%)(39) (Scenario 6), (Table 2, Supplementary Table S3). 207 Furthermore, we constructed counterfactual scenarios using data from consumer research 208 209 reporting the proportion of consumers that choose or were willing to choose products with fewer 210 'high in' FOPL symbols(42-47). We first identified foods and beverages in FLIP 2017 similar to 211 those reported in CCHS-Nutrition 2015 that would display at least one fewer 'high in' FOPL 212 symbol for nutrients of concern, including sodium. Then, to estimate 'new' dietary intakes, we 213 replaced nutritional values of identified foods for a random sample of 30%, 50%, and 70% of CCHS-Nutrition adult participants that consume at least one food that would display a 'high in' 214 symbol (Scenarios 7-9). Additionally, to estimate the potential maximum effect of FOPL, we 215 216 simulated changes for all adult participants (Scenario 10) (Table 2, Supplementary Table S3). 217 All FOPL counterfactual scenarios tested in this study are based on 'high in' FOPL evidence, which is the FOPL system recently approved in Canada. We have previously published methods 218

for all FOPL policy scenarios(20, 21). For this study, we used potential impacts of implementing
FOPL only for changes in sodium intakes.

221 Direct healthcare costs

This study followed the perspective of the public healthcare system. The model estimated direct

healthcare cost differences between the baseline and the modeled intervention. We used data

from the 2010 Economic Burden of Illness in Canada (EBIC)(48), the most recent available and

comprehensive national disease-specific costs study. Direct healthcare costs in EBIC 2010 are

reported by diagnostic category disaggregated by age/sex groups.

227 We followed previous published methods for the estimation of direct healthcare costs for each of 228 the modeled diseases(49) (i.e., total and by prevalence case). We prioritized alignment of WHO 229 ICD-10(33) codes between prevalence case data with EBIC 2010 categories, as well as disease definition as closely as possible with the Global Burden of Disease study (2019)(50). Therefore, 230 231 we first identified the best fitting EBIC diagnostic category by matching ICD-10 codes for each disease under study. We used the EBIC 2010 online tool to produce costs for each EBIC 232 category by sex (male, female) and age group (0-14 years, 15-34, 35-54, 55-64, 65-74, 75+)(51). 233 234 Direct healthcare costs are comprised of attributable (drug, hospital care – day surgery, hospital care – inpatient, hospital care – other ambulatory care, hospital care – outpatient – clinic, hospital 235 care – outpatient – emergency, and physician care) and unattributable direct costs (other 236 237 institutions, other professionals, capital, public health, administration, and other health spending). 238

EBIC diagnostic categories only provide disease-specific estimates for attributable direct costs,
but also report total unattributable direct costs; thus, unattributable direct costs were estimated

and added to cost estimates per disease. The proportion of each modeled disease's share to the 241 total attributable direct cost was estimated for each age/sex group using a method developed by 242 243 Krueger et al(52). Subsequently, this proportion was applied to the total unattributable direct costs to then include these estimates in the total direct healthcare costs for each disease. Costs 244 per disease case were then calculated by dividing estimated direct healthcare costs for each 245 246 age/sex group by prevalent cases in 2010, yielding the cost per case per year. A decision was made on using prevalent cases for each disease based on their clinical pattern of exerting costs; 247 248 hence, these were treated as prevalent cases. Lastly, healthcare costs were inflated to 2019 Canadian Dollars (CAD), and inflation factor was estimated using the 'health care' sub-index 249 from the Statistics Canada Consumer Price Index(53). Methods, sources, and direct healthcare 250 costs estimations, by each modeled disease, are described in **Table 1** and **Supplementary** 251 252 Tables S4 and S5.

253 2.3 Sensitivity analysis

Sensitivity analysis was conducted to examine the impact of uncertainty in the discount rate by applying 0% and 3% discount rate, as recommended by the CADTH(22). Additionally, we also used time horizons of 10 and 50 years.

257 2.4 Statistical analysis

The National Cancer Institute (NCI) method(54) was used to estimate Canadian adults' usual
sodium intakes and distributions for all adults and by DRI age/sex group (baseline and
counterfactual scenarios). The 1-part (amount only) model was used as zero consumption of
sodium was <5%, as recommended by Davis et al(55), which also allowed us to stratify analysis

262	by DRI age/sex groups and to remove outliers for implausible sodium intakes. Confidence
263	intervals and standard error were estimated using the bootstrap balanced repeated replication
264	method (500 replicates). Additionally, we applied sample survey weights (Statistics Canada) to
265	all analyses to ensure nationally representative estimates(35). Statistical analyses were conducted
266	using SAS version 9.4.
267	After inputting all the required data in PRIMEtime, the model estimated the avoidable ischemic

268 heart disease and stroke incidence cases, healthcare costs savings, and QALYs for each

counterfactual scenario, by sex and each disease of interest. Uncertainty intervals (95% UI) were

270 produced using Monte Carlo simulation at 5000 iterations to allow the epidemiological

271 parameters in PRIMEtime to fluctuate randomly following the distributions considered in the

272 model(24).

273 **3. Results**

274 Meeting sodium intake recommendations

Fully meeting Health Canada's sodium reduction targets was estimated to reduce mean sodium

intakes to the national sodium intake recommendations (~2,300 mg/day; 17% reduction from

current levels). This reduction in sodium intake was estimated to prevent 219,490 (95% UI,

278 73,409 – 408,630) incident cases of IHD, and 164,435 (95% UI, 56,121 – 305,770) strokes.

Approximately, 63% of prevented IHD cases were estimated in males (137,188 [95% UI, 44,185

- 280 259,658]) and 37% in females (82,303 [95% UI, 29,224 148,972]), and 57% of prevented
- 281 strokes were estimated in males (94,522 [95% UI, 31,032 179,060]) and 43% in females
- 282 (69,913 [95% UI, 25,088 126,710]). These health gains result in an overall gain of 276,185

QALYs (95% UI, 85,414 – 552,616), with 62% attributed to males and 38% to females. This
translates into CAD\$ 4,212 million (95% UI, CAD\$ 1,303 – CAD\$ 8,206) in healthcare cost
savings (69% in males, 31% in females) over the lifetime of the 2019 Canadian cohort (Tables 3
and 4, Figure 1 and 2).

- 287 Greater health and healthcare cost gains were estimated if Canadians were to meet WHO's
- population-level sodium intake recommendations (2,000 mg/day) and the Adequate Intake
- recommendation (1,500 mg/day) (**Tables 3 and 4, Figure 1 and 2**).
- 290 Implementing 'high in' front-of-pack labeling regulations
- 291 Sodium intake reduction through the implementation of FOPL regulations, as suggested by early
- evaluations of the Chilean FOPL regulations, has the potential to prevent 57,023 (95% UI,
- 293 17,350 114,447) incident cases of IHD, and 41,794 (95% UI, 12,389 85,302) strokes.
- Approximately 64% of prevented IHD cases were estimated in males (36,323 [95% UI, 10,526 –
- 295 73,593]) and 36% in females (20,701 [95% UI, 6,824 40,854]), and 58% of prevented strokes
- were estimated in males (24,443 [95% UI, 7,028 50,943]) and 42% in females (17,351 [95%
- UI, 5,361 34,359]). These health gains result in an overall gain of 74,499 QALYs (95% UI,
- 298 21,108 160,246), with 63% attributed to males and 37% to females. This translates into CAD\$
- 299 1,149 million (95% UI, CAD\$ 329 CAD\$ 2,381) in healthcare cost savings (71% in males,
- 300 29% in females) over the lifetime of the 2019 Canadian cohort (Tables 3 and 4, Figure 1 and

301 2).

- 302 Greater health and healthcare cost gains were projected based on the criteria used by WHO to
- 303 estimate FOPL cost-effectiveness and results from a FOPL systematic review and network meta-

.

.

. .

304	analysis. An increase of 34% and 64% in all outcomes was estimated, respectively, versus the
305	results based on evaluations of the Chilean FOPL (Tables 3 and 4, Figure 1 and 2).
306	Sodium intake reduction through consumer food substitution – specifically, when consumers
307	choose food products with fewer 'high in' FOPL symbols – has the potential to prevent between
308	35,930 (95% UI, 8,085 – 80,528) and 124,744 (95% UI, 40,125 – 235,643) cases of IHD, and
309	between 26,869 (95% UI, 5,235 – 61,621) and 93,129 (95% UI, 30,296 – 176,014) strokes. This
310	results in QALY gains ranging from 45,492 (95% UI, 10,281 – 106,579) to 157,628 (95% UI,
311	46,701 – 320,622), and healthcare cost savings ranging from CAD\$ 695 million (95% UI, CAD\$
312	160 – CAD\$ 1,580) to CAD\$ 2,415 million (95% UI, CAD\$ 722 – CAD\$ 4,746) over the
313	lifetime of the 2019 Canadian cohort (Tables 3 and 4, Figure 1 and 2).

- All sodium reduction strategies tested in this study were cost saving from the public healthcare
- system perspective. Estimated benefits were greater for males than females in all scenarios
- 316 tested.

317 *Sensitivity analysis*

.

. .

0.0.1.01

1 - 1 - 1

...

- 318 We examined the impact of uncertainty in the discount rate by applying discount rates of 3% and
- 319 0%. When a 3% discount rate was applied to both health and healthcare cost outcomes, a
- decrease of 44% and 39% were observed on average for QALYs and healthcare costs,
- respectively, in all scenarios. Conversely, when a 0% discount rate was applied, an increase of
- 322 96% and 78% were observed on average for QALYs and healthcare costs, respectively, in all
- 323 scenarios (See Supplementary Table S10).

Furthermore, using time horizons of 10 and 50 years, the model predicted that 7% and 76%, respectively, of estimated lifetime healthcare cost savings would occur within those time horizons. For QALYs gained, the model estimated that 4% and 67%, respectively, of estimated lifetime gains would occur within those same time horizons (See **Supplementary Table S11**).

328 **4. Discussion**

329 This study estimated the potential impact of reducing sodium intake on the incidence of ischemic heart disease and stroke cases, savings in healthcare costs, and QALYs gains. Our results 330 demonstrate that reducing sodium intakes through population-level strategies, such as 331 332 implementing sodium reduction targets and 'high in' FOPL regulations, has the potential to improve health outcomes and reduce healthcare expenditures in Canada. This adds to current 333 evidence, generated by simulation modeling studies, showing that sodium reduction strategies 334 can potentially improve health outcomes and save costs to the health system, globally(29, 56-62) 335 and in Canada(10, 19). 336

To the best of our knowledge, this is the first study estimating the potential health (QALYs) and 337 338 healthcare costs of current sodium reduction initiatives in Canada. We tested ten counterfactual 339 scenarios aiming to reduce population sodium intake. These included achieving recommended 340 sodium intakes levels (2,000 and 1,500 mg/day); meeting sodium reduction targets for packaged foods established by Health Canada (food reformulation, 2,300 mg/day); and estimated changes 341 342 in sodium intake resulting from implementing the recently approved 'high in' FOPL regulations. 343 As expected, our results showed the greatest health gains and healthcare cost savings from 344 meeting population-level sodium intake recommendations of 2,000 mg/day (441,475 QALYs; 345 CAD\$ 6,692 million in healthcare costs savings) and 1,500 mg/day (701,592 QALYs; CAD\$

10,624 million in healthcare costs savings). Our study sheds light on how far Canadians are fromachieving these maximum benefits with current sodium reduction policy initiatives.

348 For instance, for the policy initiatives tested in this study (i.e., meeting sodium reduction targets and implementing 'high in' FOPL regulations), most health and healthcare costs gains were 349 attributed to fully meeting Health Canada's sodium reduction targets (276,185 QALYs; CAD\$ 350 4,212 million in healthcare costs savings). Greater benefits were observed for males than 351 352 females, in all scenarios tested, which could be attributed to differences in sodium consumption 353 and CVD burden among Canadians males and females (9, 10, 63). Unfortunately, progress 354 evaluations have shown that compliance with the voluntary sodium reduction targets has been limited, with only 14% of food categories meeting the targets by 2017(14), indicating that to 355 meet targets by 2025(13) faster progress is needed. A robust government-led monitoring system 356 357 and higher compliance from the food industry could contribute towards increasing sodium 358 reduction progress in Canada. The consequences of not meeting established sodium reduction 359 targets for processed foods represents an important missed opportunity to generate substantial 360 health and healthcare costs gains in Canada.

361 Canada could benefit from other countries experiences that have implemented mandatory sodium reduction targets. For instance, South Africa's legislation setting mandatory maximum sodium 362 levels in foods has led to a decrease of 1.15 g/day in salt intake (~460 mg/day of sodium) in a 363 364 four-year period (2015-2019). Interestingly, similar sodium reduction levels were estimated for 365 our scenario of fully meeting sodium reduction targets(64), which indicates the feasibility of this 366 strategy. This also highlights the importance of changing the voluntary nature of sodium reduction targets in Canada to mandatory sodium reduction targets. More recently, the WHO 367 368 released the WHO global sodium benchmarks for different food categories(65). This set of

18

sodium reduction targets includes 18 main food categories and 97 food subcategories. Greater
benefits would be expected from meeting these targets in Canada, given that for several common
food categories WHO targets are more stringent than Health Canada's sodium reduction targets.
In Australia, it has been estimated that meeting WHO benchmarks, as opposed to meeting
Australian sodium reduction targets, could prevent or delay nearly three and a half times as many
diet related NCD deaths(62).

375 The potential impact of FOPL regulations was estimated through two pathways. The first was 376 based on recent FOPL evidence from observational and experimental studies (38-40) that 377 estimated changes in the content of nutrients of public health concern, including sodium, in food 378 and beverage purchases when a 'high in' FOPL was in place. Among these scenarios is one 379 based on early evaluations of the Chilean FOPL (S4), which most likely captured consumer 380 behavior change and initial industry-driven food reformulation. The health and healthcare cost 381 gains estimated from this scenario represent approximately 27% of the gains estimated from 382 meeting Health Canada's sodium reduction targets. The second pathway was based on consumer research reporting the proportion of consumers that choose or were willing to choose products 383 384 with fewer 'high in' FOPL symbols(42-47), which would only capture consumer behavior change. The estimated benefits from these scenarios range from 16% to 57% of the benefits 385 estimated from meeting Health Canada's sodium reduction targets. 386

The differences in FOPL scenarios tested are reflected in our estimates. We observed greater benefits from changes observed in food and beverage purchases in the presence of FOPL (S4-6) than from food substitution as a response of FOPL (S7-9). It is worth noting that our study focused solely on benefits from reducing sodium intake as a result of implementing FOPL in Canada. Therefore, it is expected that implementation of FOPL will result in greater health and

healthcare cost benefits, as it also targets other nutrients-of-concern (i.e., sugars and saturated 392 fats) not accounted for in our estimates. For instance, a recent study from our research group 393 394 estimated that 15% of diet related NCD deaths that could be averted or delayed due to implementation of FOPL in Canada were attributed to sodium(21). 395 A previous Canadian modeling study estimated potential heath and healthcare cost benefits, over 396 a 50-year time horizon, from reducing sodium intake levels by 1,500 mg/day(19). They 397 estimated benefits of 1,021,458 QALYs and CAD\$16,805 million in healthcare cost savings(19). 398 399 In comparison, the largest reduction we tested was a reduction in sodium intake of 1,258 mg/day 400 to achieve the AI recommendations (1,500 mg/day). Under this scenario we projected benefits of 471,748 QALYs and CAD\$ 8,083 million in healthcare cost savings over a 50-year time horizon. 401 402 Differences likely stem from variations in the magnitude of the tested sodium reduction intake 403 (reductions of 1500 mg/day vs. 1,258 mg/day), differences in methodology used to estimate 404 healthcare costs, improved management of SBP in Canada, and slight reductions observed in the 405 burden of CVDs in Canada. In the US a sodium reduction of 1,200 mg/day has been predicted to gain between 194,000 and 392,000 QALYs and save between \$10,000 to \$24,000 million in 406 407 healthcare costs(66).

This study has limitations and strengths that need to be considered in the interpretation of our results. First, scenario modeling is an analytical technique; hence, results are as appropriate and generalizable as the data, assumptions and constraints that are applied to the mathematical model(67). To mitigate this, we used Canadian–specific and nationally representative data as inputs for the model. Additionally, our counterfactual sodium reduction intervention scenarios are based on Canadian sodium reduction targets and the most recent available evidence on the impact of FOPL regulations. We followed the perspective of the public healthcare system; hence,

the costs of implementing the sodium reduction interventions were not considered. Although 415 population-wide sodium reduction interventions in Canada were estimated to cost CAD\$2.02 per 416 417 person annually (Canadian population in 2019: 38 million approximately), these costs would be minimal in comparison with savings in healthcare costs(19, 68). These costs included 418 government led industry agreements to reduce sodium in packaged foods, government 419 420 monitoring of industry compliance, and public health campaigns(19, 68). We also did not consider societal gains in our modeling, such as productivity gains from preventing premature 421 422 deaths or disease burden.

423 Furthermore, we focused on the potential health effects of reducing sodium intake, specifically 424 health effects from IHD and stroke, the leading causes of death globally. However, recent studies have estimated potential effects of reducing sodium on other diseases such as chronic kidney 425 426 disease and stomach cancer (58, 59, 69, 70). Therefore, our estimations of the potential benefits 427 of reducing population-level sodium intake are conservative, considering that reducing sodium 428 intake could also have positive effects on other diseases. Lastly, this study used data for the 429 entire Canadian population without considering equity aspects. Future research can expand our 430 work by examining the differential impacts of reducing sodium intake among diverse subgroups.

431 This study also has strengths to consider. Dietary sodium intake data was estimated using data

432 from a nationally representative sample of the Canadian population (CCHS-Nutrition 2015).

433 Surveys of this kind are usually prone to biases related to misreporting due to recall bias.

434Nevertheless, CCHS-Nutrition 2015 used the Automated Multiple Pass Method to reduce the

435 impact of such reporting errors. We used the NCI method to estimate usual sodium intakes and

436 adjusted for age, sex, dietary misreporting status, weekend/weekday, and sequence of dietary

437 recall. For modeling we used the PRIMEtime model, a robust, validated and widely used

21

proportional multi-state lifetable model(23, 24). Strengths and limitations of the model have been
previously published(24). We also conducted sensitivity analysis to examine the impact of
uncertainty in the discount rate by applying 0% and 3% discount rates, as has been
recommended(22). As expected, variations in discount rates, both higher and lower than our
main analysis (1.5% discount rate), had a significant impact on health and healthcare cost
outcomes.

Our findings provide evidence for policymakers and stakeholders of the potential benefits of 444 445 reducing sodium intake through strategies widely discussed in Canada that target packaged 446 foods. This is especially relevant because packaged foods are the main source of sodium intake for Canadians(9). Multicomponent strategies have proven to be more effective and are necessary 447 448 for reaching the national and global sodium recommendations(11, 71). Therefore, in addition to 449 moving from voluntary to mandatory sodium reduction targets for packaged foods and 450 implementing 'high in' FOPL regulations, other initiatives should be considered for Canadians to 451 meet population-level sodium intake recommendations (2,000 and 1,500 mg/day). These could 452 include setting sodium reduction targets for restaurant foods, restricting marketing of foods 'high 453 in' sodium, enabling healthy food environments in public settings by providing lower sodium 454 options, regulating the digital food environment to require nutritional information, encouraging 455 the use of low-sodium, potassium-enriched salt, and adopting approaches such as social marketing to develop behavior change communication and mass media campaigns(11, 72, 73). A 456 457 combination of strategies, as has been recommended by the WHO's SHAKE Technical Package for Salt Reduction(11), would be of most benefit from a public health standpoint. 458

459 **5.** Conclusions

22

460	Reducing population-level sodium intakes is feasible and has the potential to improve health
461	outcomes and save healthcare costs in Canada. From the interventions tested most health and
462	healthcare costs gains were attributed to fully meeting sodium reduction targets, which highlights
463	the importance of changing the voluntary nature of these targets to mandatory. A combination of
464	strategies, mandatory sodium reduction targets and implementation of the 'high in' FOPL
465	symbol would be of most benefit from a public health standpoint. Thus, policymakers and
466	stakeholders need to strengthen, and coordinate actions aimed at reducing sodium levels in the
467	Canadian food supply. This is crucial for improving health outcomes and saving healthcare costs.
468	Future studies could leverage this work to evaluate potential variations in effects among diverse

469 subgroups in Canada.

470 **Conflict of interest**

- 471 The authors declare that the research was conducted in the absence of any commercial or
- 472 financial relationships that could be construed as a potential conflict of interest.

473 Authors' contributions

- 474 NF, AJ, and MRL conceptualized the study design; NF, AJ, BAC, LC, EN and MRL interpreted
- the findings; NF conducted the study, wrote the original draft, and performed the statistical
- analysis. All authors critically reviewed and approved the final manuscript.

477 **Funding**

- 478 This research was funded by Canadian Institutes of Health Research (CIHR) operating grants
- 479 (PJT-165858; SA2-152805; Healthy Cities Training Award). <u>https://cihr-irsc.gc.ca/e/193.html</u>.
- 480 The funders had no role in study design, data collection and analysis, decision to publish, or
- 481 preparation of the manuscript.

482 Acknowledgments

The authors would like to thank Professor Peter Scarborough, University of Oxford, for allowing
us to use the PRIMEtime model and discussing its application; as well as current and past
L'Abbe lab members who worked on various aspects of the FLIP database, especially Anthea
Christoforou who worked and published data on the sodium reformulation scenario used in this
manuscript. Furthermore, the authors would like to acknowledge the assistance of Arantxa
Bonifaz Rosas with the collection of Canadian healthcare cost data.

489

490 Data Availability Statement

- 491 Analytic code (R) can be made available to researchers upon request to the author. *Canadian*
- 492 *Community Health Survey-Nutrition 2015 Public Use Microdata File (PUMF)* data is publicly
- and freely available without restriction at Statistics Canada,
- 494 https://www150.statcan.gc.ca/n1/en/catalogue/82M0024X
- 495 Canadian population demographics, healthcare costs and epidemiology data associated with
- 496 ischemic heart disease and stroke were obtained from publicly available sources also detailed
- 497 in the main manuscript.
- 498 https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501
- 499 https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310070901
- 500 <u>https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310014701</u>
- 501 <u>https://health-infobase.canada.ca/ccdss/data-tool/</u>
- 502 https://cost-illness.canada.ca/custom-personnalise/national.php

Parameter	Data source	Details	Year
Canadian population demographics	Statistics Canada: Table 17-10-0005-01 (Formerly CANSIM 051-0001)	1y age/sex groups 0-100+ years	2019
Deaths	Statistics Canada: Table: 13-10-0709-01 (Formerly CANSIM 102-0503)	5y age/sex groups 0–100+ years	2019
Disease-specific deaths	Statistics Canada: Table: 13-10-0147-01 (Formerly CANSIM 102-0529)	5y age/sex groups 0–90+ years	2019
Disease-specific prevalence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Disease-specific incidence	Canadian Chronic Disease Surveillance System	5y age/sex groups 20–90+ years	2019
Case fatalities	Were derived from Statistics Canada estimates of incidence, prevalence, and deaths, using the <i>disbayes</i> R package.	1y age/sex groups 0–100+ years	2019
SBP estimates	Statistics Canada: Table: 13-10-0326-01 (Formerly CANSIM 117-0008)	different age/sex groups 6-79 years	2019
Sodium intake	Canadian Community Health Survey- Nutrition 2015	DRI age/sex groups 19+ years	2015
Direct healthcare costs, disease-specific	Economic Burden of Illness in Canada	different age/sex groups 0–75+ years	2010
Consumer price index	Statistics Canada: Table 18-10-0005-01 (Formerly CANSIM 326-0021)	health care sub-index	2019
Utility weights	Parameters used to estimate disease-specific and background utility weights were extracted from a UK catalogue of EQ-5D scores	disease-specific prevalence and incidence weights; and by 10y age bands	2011
Relative risks	Disease associated relative risks were derived from a systematic review and meta-analysis (Per 20 mmHg of SBP)	evidence from prospective studies; different age/sex groups <49-79+ years	2002

503	Table 1. Key data sources used for the application of the PRIMEtime Salt model in Canada
504	

505 SBP, systolic blood pressure.

506 **Table 2.** Sodium reduction counterfactual scenarios

507

Counterfactual scenarios		Based on	Parameters modeled	Δ Sodium *	Δ Salt [*]
Meeting sodium intake recommendations	S1: AI sodium intake recommendations (1,500 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 1,258 mg/day	- 3.14 g/day
	S2: WHO sodium intake recommendations (2,000 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Estimated sodium intakes by DRI age/sex group	- 758 mg/day	- 1.89 g/day
	S3: Sodium reduction targets for packaged foods, reformulation (2,300 mg/day)	Flexner N, Christoforou A, et al (2023) (10)	Food & beverages with a sodium target	- 459 mg/day	- 1.15 g/day
Implementing 'high in' FOPL regulations (food and	S4: Changes in food & beverage purchases (Chilean FOPL experience) (20)	Taillie L, et al (2021) (38)	Changes in sodium content of food & beverage purchases	- 128 mg/day	- 0.32 g/day
beverage purchases)	S5: Based on WHO criteria to estimate cost- effectiveness of FOPL policies (20)	WHO (2022) (40)	Changes in sodium content of food & beverage purchases	- 174 mg/day	- 0.44 g/day
	S6: Based on a FOPL systematic review and network meta-analysis (20)	Song J, et al (2021) (39)	Changes in sodium content of food & beverage purchases	- 212 mg/day	- 0.53 g/day
Implementing 'high in' FOPL regulations (food	S7: Based on food substitution for 30% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 73 mg/day	- 0.18 g/day
substitution)	S8: Based on food substitution for 50% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 131 mg/day	- 0.33 g/day
	S9: Based on food substitution for 70% of CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 182 mg/day	- 0.45 g/day
	S10: Based on food substitution for all CCHS-Nutrition 2015 adult participants	Flexner N, et al (2023) (21)	Food substitution with a healthier food alternative	- 259 mg/day	- 0.65 g/day

 508
 *These values are overall intervention effect. Intervention effect by DRI age/sex group, as imputed in the PRIMEtime model, are detailed in Supplementary Table

509 S3. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). We considered the potential impacts of FOPL implementation solely

510 for changes in sodium intakes. FOPL, front-of-pack labeling; WHO, World Health Organization; AI, Adequate Intake; mg, milligram; CCHS, Canadian

511 Community Health Survey.



512 Figure 1. Estimated QALY gained over the lifetime of the 2019 cohort, by sex and sodium reduction strategy

513

The potential QALYs gained were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual scenario have

been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on WHO sodium intake recommendations of 2,000 mg/day and the AI

recommendations of 1,500 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets for packaged

517 foods. The FOPL-changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL-

518 food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products with fewer

519 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack

520 labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

- 521 Figure 2. Estimated healthcare cost savings (CAD\$ million) over the lifetime of the 2019 cohort, by sex and sodium reduction
- 522 strategy

523





524

525 The potential healthcare cost savings were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full details of each counterfactual

- 526 scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios were based on the AI recommendations of 1,500 mg/day and the WHO
- 527 sodium intake recommendations of 2,000 mg/day. The sodium target scenario was based on fully meeting Health Canada's voluntary sodium reduction targets
- 528 for packaged foods. The FOPL–changes in F&B purchase scenarios were based on recent FOPL evidence from observational and experimental studies(38-40).
- 529 The FOPL-food substitution scenarios were based on consumer research reporting the proportion of consumers that choose or were willing to choose products 530 with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-
- pack labeling; WHO, World Health Organization; AI, Adequate Intake; QALY, Quality-Adjusted Life Year; F&B, food and beverages.

532 **Table 3.** Prevented disease incident cases over the lifetime of the cohort, by sex and sodium

533 reduction strategy

Counterfactual scenarios		IHD incidence cases	%	Stroke incidence cases	%
su	S1: Meeting AI sodium intake recommendations (1.500 mg/day)	559 205 (101 157 - 1 022 005)	1000/	419 291 (147 760 762 690)	1000/
latio	$M_{alag} \left(0.50 / 111 \right)$	556,595(191,157 - 1,052,085)	620/	418,281 (147,700 - 702,089)	570/
ienc	Males (95% UI)	344,273 (111,385 – 647,013)	02% 280/	230,728 (79,040 - 439,203)	57%
umo	Females (95% 01)	214,123 (79,572 - 385,070)	38%	181,555 (08,114 - 525,425)	43%
reco	S2: Meeting WHO sodium intake recommendations		10001		1000
ake	(2,000 mg/day)	350,142 (117,927 – 649,693)	100%	261,877 (88,387 – 481,374)	100%
int i	Males (95% UI)	217,586 (70,367 – 410,138)	62%	149,596 (48,512 – 278,702)	57%
diun	Females (95% UI)	132,556 (47,561 – 239,555)	38%	112,280 (39,875 – 202,672)	43%
ing soc	S3: Meeting sodium reduction targets for packaged foods (2,300 mg/day)	219,490 (73,409 - 408,630)	100%	164,435 (56,121 – 305,770)	100%
deet	Males (95% UI)	137,188 (44,185 – 259,658)	63%	94,522 (31,032 - 179,060)	57%
N	Females (95% UI)	82,303 (29,224 - 148,972)	37%	69,913 (25,088 - 126,710)	43%
erage	S4: Changes in food & beverage purchases (Chilean experience)	57,023 (17,350 – 114,447)	100%	41,794 (12,389 - 85,302)	100%
bev	Males (95% UI)	36,323 (10,526 - 73,593)	64%	24,443 (7,028 - 50,943)	58%
and	Females (95% UI)	20,701 (6,824 - 40,854)	36%	17,351 (5,361 – 34,359)	42%
n food chases	S5: Based on WHO criteria to estimate cost- effectiveness of FOPL policies	76,555 (24,471 – 150,693)	100%	56,322 (18,202 - 111,634)	100%
es ii purc	Males (95% UI)	48,704 (14,968 – 96,967)	64%	32,914 (10,308 - 65,871)	58%
lang	Females (95% UI)	27,851 (9,503 - 53,726)	36%	23,409 (7,894 - 45,763)	42%
PL – cl	S6: Based on a FOPL systematic review and network meta-analysis	93,714 (31,069 - 181,713)	100%	69,000 (23,030 - 135,388)	100%
FO	Males (95% UI)	59,803 (19,070 - 117,662)	64%	40,490 (13,046 - 80,568)	59%
	Females (95% UI)	33,911 (11,999 – 64,051)	36%	28,511 (9,985 - 54,820)	41%
	S7: Based on food substitution for 30% of CCHS- Nutrition 2015 adult participants	35,930 (8,058 - 80,528)	100%	26.869 (5.235 - 61.621)	100%
	Males (95% UI)	22,968 (5,336 - 51,212)	64%	15,860 (3,221 – 36,350)	59%
_	Females (95% UI)	12,962 (2,722 – 29,315)	36%	11,009 (2,013 – 25,271)	41%
stitution	S8: Based on food substitution for 50% of CCHS- Nutrition 2015 adult participants	63,013 (19,800 – 127,007)	100%	46,868 (14,668 – 94,881)	100%
dus	Males (95% UI)	40,472 (12,467 - 82,378)	64%	27,767 (8,508 - 56,851)	59%
poo	Females (95% UI)	22,541 (7,332 - 44,628)	36%	19,101 (6,160 - 38,030)	41%
PL – f	S9: Based on food substitution for 70% of CCHS- Nutrition 2015 adult participants	86,135 (28,713 - 166,394)	100%	63,961 (21,187 – 124,102)	100%
FC	Males (95% UI)	55,461 (17,911 – 108,730)	64%	37,984 (12,216 – 74,661)	59%
	Females (95% UI)	30,674 (10,802 - 57,664)	36%	25,977 (8,971 – 49,441)	41%
	S10: Based on food substitution for all CCHS- Nutrition 2015 adult participants	124,744 (40,125 – 235.643)	100%	93,129 (30,296 - 176.014)	100%
	Males (95% UI)	78,998 (24,224 – 151,268)	63%	54,299 (16,845 – 104,141)	58%
	Females (95% UI)	45,746 (15,901 – 84,375)	37%	38,830 (13,451 – 71,873)	42%

- 535 The potential health impacts were estimated using the PRIMEtime model(24), with inputs described in Table 1. Full
- details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium intake goal scenarios
- 537 were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake recommendations of
- 538 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health Canada's voluntary sodium
- reduction targets for packaged foods. The FOPL–changes in F&B purchase scenarios (S4-6) were based on recent
- 540 FOPL evidence from observational and experimental studies(38-40). The FOPL–food substitution scenarios (S7-10)
- 541 were based on consumer research reporting the proportion of consumers that choose or were willing to choose
- 542 products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts of FOPL implementation
- solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, ischemic heart disease; WHO, World
- Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey.

545 **Table 4.** Estimated health gains and healthcare cost savings over the lifetime of the cohort, by

sex and sodium reduction strategy

Counterfactual scenarios		QALY gains %		Healthcare cost savings (CAD\$ million)	%
lations	S1: Meeting AI sodium intake recommendations (1.500 mg/day)	701 502 (225 670 1 202 220)	100%	10 624 (2 256 - 20 665)	100%
	Males (95% III)	$425\ 297\ (126\ 968\ -\ 860\ 372)$	61%	7 295 (2 183 - 14 410)	100% 69%
nenc	Females (95% UI)	276295(98711 - 532858)	39%	3,329(1,173 - 6,255)	31%
omr	S2: Masting WHO sodium intoka recommendations	270,299 (90,711 - 352,050)	3770	5,527 (1,175 - 0,255)	5170
e rec	(2,000 mg/day)	441 475 (135 508 - 891 597)	100%	6 692 (2 092 - 13 017)	100%
ntake	Males (95% UI)	269.816 (77.889 - 555.809)	61%	4.626(1.383 - 9.108)	69%
m ii	Females (95% UI)	171,659 (57,619 – 335,788)	39%	2,067 (708 – 3,909)	31%
odiu	S3: Meeting sodium reduction targets for nackaged	, , , , , ,		· 、 · · /	
ng s	foods (2,300 mg/day)	276,185 (85,414 - 552,616)	100%	4.212 (1.303 - 8.206)	100%
leeti	Males (95% UI)	169,889 (50,166 – 344,868)	62%	2,926 (868 – 5,769)	69%
N	Females (95% UI)	106,296 (35,248 - 207,748)	38%	1,286 (435 – 2,437)	31%
e	S4: Changes in food & beverage purchases				
erag	(Chilean experience)	74,499 (21,108 – 160,246)	100%	1,149 (329 - 2,381)	100%
bev	Males (95% UI)	46,889 (12,607 – 102,243)	63%	814 (220 - 1,708)	71%
and	Females (95% UI)	27,609 (8,501 - 58,003)	37%	336 (109 - 673)	29%
cood ases	S5: Based on WHO criteria to estimate cost-				
s in 1 trch:	effectiveness of FOPL policies	99,867 (29,314 – 210,195)	100%	1,535 (455 – 3,119)	100%
nges pu	Males $(95\% \text{ UI})$	62,782(17,670 - 134,336)	63% 27%	1,085(308 - 2,231)	/1%
cha		57,084 (11,044 - 75,859)	57%	449 (147 - 888)	29%
$^{-1}$	S6: Based on a FOPL systematic review and network meta-analysis	121.817 (37.065 - 252.387)	100%	1.876 (573 - 3.802)	100%
FOI	Males (95% UI)	76.734 (22.375 – 161.718)	63%	1,329(391 - 2.725)	71%
	Females (95% UI)	45,083 (14,690 – 90,669)	37%	548 (181 – 1,077)	29%
	S7: Based on food substitution for 30% of CCHS.				
	Nutrition 2015 adult participants	45,492 (10,281 - 106,579)	100%	695 (160 - 1,580)	100%
	Males (95% UI)	28,620 (6,375 - 68,250)	63%	492 (110 -1,123)	71%
u	Females (95% UI)	16,872 (3,906 – 38,329)	37%	204 (50 - 457)	29%
stitutio	S8: Based on food substitution for 50% of CCHS- Nutrition 2015 adult participants	80,321 (23,373 – 169,543)	100%	1,231 (367 – 2,549)	100%
sqns	Males (95% UI)	50,867 (14,373 - 108,277)	63%	875 (254 – 1,835)	71%
poo	Females (95% UI)	29,454 (9,001 - 61,265)	37%	356 (113 - 714)	29%
PL – f	S9: Based on food substitution for 70% of CCHS- Nutrition 2015 adult participants	110.063 (34.011 - 228.868)	100%	1.688 (512 - 3.427)	100%
FO	Males (95% UI)	69.860 (20.880 - 147.630)	63%	1.202(351 - 2.468)	71%
	Females (95% UI)	40,203 (13,131 - 81,239)	37%	486 (161 – 959)	29%
	S10: Based on food substitution for all CCHS-	· · · · · · · · · /		· · · · · /	
	Nutrition 2015 adult participants	157,628 (46,701 - 320,622)	100%	2,415 (722 – 4,746)	100%
	Males (95% UI)	98,309 (27,375 - 203,349)	62%	1,696 (482 – 3,376)	70%
	Females (95% UI)	59,318 (19,326 – 117,273)	38%	719 (239 – 1,370)	30%

- 547 The potential health gains and healthcare cost savings were estimated using the PRIMEtime model(24), with inputs
- described in Table 1. Full details of each counterfactual scenario have been published elsewhere(10, 20, 21). Sodium
- 549 intake goal scenarios were based on the AI recommendations of 1,500 mg/day (S1) and the WHO sodium intake
- recommendations of 2,000 mg/day (S2). The sodium target scenario (S3) was based on fully meeting Health
- 551 Canada's voluntary sodium reduction targets for packaged foods. The FOPL-changes in F&B purchase scenarios
- 552 (S4-6) were based on recent FOPL evidence from observational and experimental studies(38-40). The FOPL–food
- substitution scenarios (S7-10) were based on consumer research reporting the proportion of consumers that choose
- or were willing to choose products with fewer 'high in' FOPL symbols(42-47). We considered the potential impacts
- 555 of FOPL implementation solely for changes in sodium intakes. FOPL, front-of-pack labeling; IHD, WHO, World
- Health Organization; AI, Adequate Intake; UI, Uncertainty Interval; CCHS, Canadian Community Health Survey;
- 557 QALY, Quality-Adjusted Life Year; CAD\$, Canadian dollars.

558 **References**

559 1. Institute for Health Metrics and Evaluation (IHME). GBD Compare Seattle, WA: IHME, University of Washington, 2019.2019 [Available from: http://vizhub.healthdata.org/gbd-560 561 compare. 562 2. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al. Global sodium consumption and death from cardiovascular causes. New England Journal of Medicine. 563 564 2014;371(7):624-34. 565 3. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for 566 the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A 567 568 Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018;71(19):e127-569 570 e248. 4. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 571 Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 572 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982-3021. 573 574 World Health Organization. Noncommunicable diseases country profiles 2018 2018 5. [Available from: https://apps.who.int/iris/handle/10665/274512. 575 World Health Organization. Tackling NCDs: 'best buys' and other recommended 576 6. interventions for the prevention and control of noncommunicable diseases 2017 [Available from: 577 578 https://apps.who.int/iris/handle/10665/259232. World Health Organization. Saving lives, spending less: a strategic response to 579 7. 580 noncommunicable diseases Geneva, Switzerland.2018 [Available from: 581 https://apps.who.int/iris/handle/10665/272534. World Health Organization. Salt reduction 2020 [Available from: 582 8. https://www.who.int/news-room/fact-sheets/detail/salt-reduction. 583 Health Canada. Sodium Intake of Canadians in 2017 2018 [Available from: 584 9. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/food-585 nutrition/sodium-intake-canadians-2017/2017-sodium-intakes-report-eng.pdf. 586 Flexner N, Christoforou AK, Bernstein JT, Ng AP, Yang Y, Fernandes Nilson EA, et al. 587 10. Estimating Canadian sodium intakes and the health impact of meeting national and WHO 588 recommended sodium intake levels: A macrosimulation modelling study. PLOS ONE. 589 590 2023;18(5):e0284733. World Health Organization. The SHAKE Technical Package for Salt Reduction. Geneva: 591 11. 592 WHO;2016. [Available from: 593 https://apps.who.int/iris/bitstream/handle/10665/250135/9789241511346-eng.pdf?sequence=1. Health Canada. Healthy Eating Strategy 2016 [Available from: 12. 594 https://www.canada.ca/en/health-canada/services/publications/food-nutrition/healthy-eating-595 596 strategy.html. Goverment of Canada. Voluntary sodium reduction targets for processed foods 2020-597 13. 2025 2020 [Available from: https://www.canada.ca/en/health-canada/services/food-598 nutrition/healthy-eating/sodium/sodium-reduced-targets-2020-2025.html. 599 Health Canada. Sodium Reduction in Processed Foods in Canada: An Evaluation of 600 14. Progress toward Voluntary Targets from 2012 to 2016 2018 [Available from: 601 https://www.canada.ca/content/dam/hc-sc/documents/services/food-nutrition/legislation-602

- 603 guidelines/guidance-documents/guidance-food-industry-reducing-sodium-processed-foods 604 progress-report-2017/pub1-eng.pdf.
- 605 15. Goverment of Canada. Regulations Amending the Food and Drug Regulations (Nutrition
- 606 Symbols, Other Labelling Provisions, Vitamin D and Hydrogenated Fats or Oils): SOR/2022-
- 168 2022 [Available from: <u>https://canadagazette.gc.ca/rp-pr/p2/2022/2022-07-20/html/sor-</u>
 dors168-eng.html.
- 609 16. Scarborough P, Harrington RA, Mizdrak A, Zhou LM, Doherty A. The preventable risk
- 610 integrated ModEl and its use to estimate the health impact of public health policy scenarios.611 Scientifica. 2014;2014.
- 612 17. Webber L, Mytton OT, Briggs AD, Woodcock J, Scarborough P, McPherson K, et al.
 613 The Brighton declaration: the value of non-communicable disease modelling in population health
 614 sciences. European journal of epidemiology. 2014;29:867-70.
- 18. Hope SF, Webster J, Trieu K, Pillay A, Ieremia M, Bell C, et al. A systematic review of
- economic evaluations of population-based sodium reduction interventions. PLoS One. 2017;12(3):e0173600
- 617 2017;12(3):e0173600.
- 618 19. Qureshi H. The Economic Impact of Dietary Sodium Reduction in Canada. Calgary,619 Canada: University of Calgary; 2017.
- Flexner N, Ng AP, Ahmed M, Khandpur N, Acton RB, Lee JJ, et al. Estimating the
 dietary and health impact of implementing front-of-pack nutrition labeling in Canada: A
 macrosimulation modeling study. Frontiers in Nutrition. 2023;10.
- Flexner N, Ahmed M, Mulligan C, Bernstein JT, Christoforou AK, Lee JJ, et al. The
 estimated dietary and health impact of implementing the recently approved 'high in' front-ofpackage nutrition symbol in Canada: a food substitution scenario modeling study. Frontiers in
 Nutrition. 2023;10.
- 627 22. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the
 628 economic evaluation of health technologies: Canada. Ottawa: CADTH; 2017 Mar.
- 23. Dötsch-Klerk M, Bruins MJ, Detzel P, Martikainen J, Nergiz-Unal R, Roodenburg AJ, et
 al. Modelling health and economic impact of nutrition interventions: a systematic review.
- European Journal of Clinical Nutrition. 2022:1-14.
- 632 24. Cobiac LJ, Law C, Scarborough P. PRIMEtime: an epidemiological model for informing
 633 diet and obesity policy. medRxiv. 2022:2022.05. 18.22275284.
- Cobiac LJ, Scarborough P, Kaur A, Rayner M. The Eatwell guide: modelling the health
 implications of incorporating new sugar and fibre guidelines. PLoS One. 2016;11(12).
- Briggs ADM, Cobiac LJ, Wolstenholme J, Scarborough P. PRIMEtime CE: a multistate
 life table model for estimating the cost-effectiveness of interventions affecting diet and physical
 activity. BMC Health Serv Res. 2019;19(1):485.
- 639 27. Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is Doctor Referral to a Low-
- Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?
 Obesity. 2019;27(3):391-8.
- 642 28. Mytton OT, Boyland E, Adams J, Collins B, O'Connell M, Russell SJ, et al. The
- 643 potential health impact of restricting less-healthy food and beverage advertising on UK television
- between 05.30 and 21.00 hours: A modelling study. PLoS medicine. 2020;17(10):e1003212.
- Alonso S, Tan M, Wang C, Kent S, Cobiac L, MacGregor GA, et al. Impact of the 2003
- to 2018 Population Salt Intake Reduction Program in England: A Modeling Study. Hypertension.
 2021;77(4):1086-94.

648 30. Cobiac LJ, Scarborough P. Modelling the health co-benefits of sustainable diets in the

- 649 UK, France, Finland, Italy and Sweden. European journal of clinical nutrition. 2019;73(4):624-650 33.
- 651 31. Aminde LN, Phung HN, Phung D, Cobiac LJ, Veerman JL. Dietary salt reduction,
- 652 prevalence of hypertension and avoidable burden of stroke in Vietnam: modelling the health and 653 economic impacts. Frontiers in public health. 2021;9:682975.
- Jackson C. Bayesian estimation of chronic disease epidemiology from incomplete data:
 the disbayes package 2023 [Available from:
- 656 https://chjackson.github.io/disbayes/articles/disbayes.html#data-required-by-the-bayesian-model.
- 657 33. World Health Organization. International Statistical Classification of Diseases and
- 658 Related Health Problems 10th Revision 2016 [Available from:
- 659 <u>https://icd.who.int/browse10/2016/en#/I20-I25</u>.
- 660 34. Jackson C, Zapata-Diomedi B, Woodcock J. Bayesian multistate modelling of incomplete
- chronic disease burden data. Journal of the Royal Statistical Society Series A: Statistics in
 Society. 2023;186(1):1-19.
- 663 35. Health Canada. 2015 Canadian Community Health Survey Nutrition. Reference Guide
- to Understanding and Using the Data 2017 [Available from: <u>https://www.canada.ca/en/health-</u>
 <u>canada/services/food-nutrition/food-nutrition-surveillance/health-nutrition-surveys/canadian-</u>
- 666 <u>community-health-survey-cchs/reference-guide-understanding-using-data-2015.html</u>.
- 667 36. National Academies of Sciences Engineering and Medicine. Dietary Reference Intakes
- 668 Collection 2022 [Available from: <u>https://nap.nationalacademies.org/collection/57/dietary-</u> 669 reference-intakes.
- 670 37. Bernstein JT, Christoforou AK, Flexner N, L'Abbe MR. Comparing the nutritional
- 671 composition of foods and beverages in the Canadian Nutrient File to a large representative
- database of Canadian prepackaged foods and beverages. PLOS ONE. 2023;18(3):e0280028.
- Taillie LS, Bercholz M, Popkin B, Reyes M, Colchero MA, Corvalán C. Changes in food
 purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before
- 674 purchases after the Chinean policies on food fabelling, marketing, and safes in s 675 and after study. The Lancet Planetary Health. 2021;5(8):e526-e33.
 - Song J, Brown MK, Tan M, MacGregor GA, Webster J, Campbell NR, et al. Impact of
 color-coded and warning nutrition labelling schemes: A systematic review and network metaanalysis. PLoS Medicine. 2021;18(10):e1003765.
 - 40. World Health Organization. Technical briefing for Appendix 3 of the Global Action Plan
 for Non-Communicable Diseases 2022 [Available from:
 - 681 <u>https://www.who.int/teams/noncommunicable-diseases/updating-appendix-3-of-the-who-global-</u>
 682 <u>ncd-action-plan-2013-2030</u>.
 - 41. Appelhans BM, French SA, Tangney CC, Powell LM, Wang Y. To what extent do food
 purchases reflect shoppers' diet quality and nutrient intake? International Journal of Behavioral
 Nutrition and Physical Activity. 2017;14(1):1-10.
- 686 42. Ministerio de Salud de Chile. Informe de evaluación de la implementación de la Ley
- 687 sobre composición nutricional de los alimentos y su publicidad 2017 [Available from:
- 688 <u>https://www.minsal.cl/wp-content/uploads/2017/05/Informe-Implementaci%c3%b3n-Ley-</u>
- 689 <u>20606-junio-2017-PDF.pdf</u>.
- Ministerio de Salud de Chile. Informe de evaluación de la implementación de la ley sobre
 composición nutricional de los alimentos y su publicidad 2018 [Available from:
- 692 <u>https://www.minsal.cl/wp-content/uploads/2018/05/Informe-Implementaci</u>ón-Ley-20606-
- 693 febrero-18-1.pdf.

44. Ministerio de Salud de Chile. Informe sobre evaluaciones de la Ley Nº 20.606 sobre 694 composicion nutricional de los alimentos y su publicidad 2021 [Available from: 695 https://www.minsal.cl/wp-content/uploads/2022/02/EVALUACION-LEY-DE-ALIMENTOS-696 697 oct2021.pdf. 45. Bromberg M, Sinai T, Keinan-Boker L, Endevelt R, Frankenthal D. Current use of 698 nutrition facts tables and attitudes towards new red and green front-of-package labels among 699 Israeli consumers. International Journal of Food Sciences and Nutrition. 2022;73(2):230-7. 700 701 Shahrabani S. The impact of Israel's Front-of-Package labeling reform on consumers' 46. 702 behavior and intentions to change dietary habits. Israel Journal of Health Policy Research. 2021;10(1):1-11. 703 704 47. Mansfield ED, Ibanez D, Chen F, Chen E, de Grandpré E. Efficacy of "High in" Nutrient 705 Specific Front of Package Labels—A Retail Experiment with Canadians of Varying Health Literacy Levels. Nutrients. 2020;12(10):3199. 706 Public Health Agency of Canada. Economic Burden of Illness in Canada, 2010 2018 707 48. 708 [Available from: https://www.canada.ca/en/public-health/services/publications/science-researchdata/economic-burden-illness-canada-2010.html. 709 Jones AC. Predicting the potential health and economic impact of a sugary drink tax in 710 49. Canada: a modelling study: UWSpace; 2018. 711 Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 712 50. 713 2019) Data Resources 2019 [Available from: https://ghdx.healthdata.org/gbd-2019. 714 Goverment of Canada. Economic Burden of Illness in Canada custom report generator 51. 715 2010 [Available from: https://cost-illness.canada.ca/custom-personnalise/national.php. Krueger H, Krueger J, Koot J. Variation across Canada in the economic burden 716 52. 717 attributable to excess weight, tobacco smoking and physical inactivity. Canadian journal of 718 Public health. 2015;106(4):e171-e7. 719 53. Canada S. Consumer Price Index, annual average, not seasonally adjusted. Statistics Canada: Table 18-10-0005-01 (formerly CANSIM 326-0021) 2019 [Available from: 720 721 https://www150.statcan.gc.ca/t1/tbl1/en/cv.action?pid=1810000501. National Cancer Institute. Usual Dietary Intakes: SAS Macros for the NCI Method 2018 722 54. 723 [Available from: https://epi.grants.cancer.gov/diet/usualintakes/macros.html. Davis KA, Gonzalez A, Loukine L, Qiao C, Sadeghpour A, Vigneault M, et al. Early 724 55. experience analyzing dietary intake data from the Canadian Community Health Survey— 725 726 nutrition using the National Cancer Institute (NCI) method. Nutrients. 2019;11(8):1908. 727 56. Nilson EAF, Pearson-Stuttard J, Collins B, Guzman-Castillo M, Capewell S, O'Flaherty M, et al. Estimating the health and economic effects of the voluntary sodium reduction targets in 728 Brazil: microsimulation analysis. BMC medicine. 2021;19(1):1-10. 729 Shangguan S, Mozaffarian D, Sy S, Lee Y, Liu J, Wilde PE, et al. Health Impact and 730 57. Cost-Effectiveness of Achieving the National Salt and Sugar Reduction Initiative Voluntary 731 732 Sugar Reduction Targets in the United States: A Micro-Simulation Study. Circulation. 2021. Aminde LN, Wanjau MN, Cobiac LJ, Veerman JL. Estimated Impact of Achieving the 733 58. Australian National Sodium Reduction Targets on Blood Pressure, Chronic Kidney Disease 734 735 Burden and Healthcare Costs: A Modelling Study. Nutrients. 2023;15(2). 736 59. Aminde LN, Cobiac LJ, Phung D, Phung HN, Veerman JL. Avoidable burden of stomach cancer and potential gains in healthy life years from gradual reductions in salt consumption in 737 738 Vietnam, 2019–2030: A modelling study. Public Health Nutrition. 2023;26(3):586-97.

73960.Aminde LN, Cobiac L, Veerman JL. Cost-effectiveness analysis of population salt

- reduction interventions to prevent cardiovascular disease in Cameroon: mathematical modelling
 study. BMJ open. 2020;10(11):e041346.
- Trieu K, Coyle DH, Afshin A, Neal B, Marklund M, Wu JH. The estimated health impact
 of sodium reduction through food reformulation in Australia: A modeling study. PLoS Medicine.
 2021;18(10):e1003806.
- 745 62. Trieu K, Coyle DH, Rosewarne E, Shahid M, Yamamoto R, Nishida C, et al. Estimated
- Dietary and Health Impact of the World Health Organization's Global Sodium Benchmarks on
 Packaged Foods in Australia: a Modeling Study. Hypertension. 2023.
- 748 63. Pacheco C, Mullen KA, Coutinho T, Jaffer S, Parry M, Van Spall HGC, et al. The
- 749 Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and
- Management of Cardiovascular Disease in Women Chapter 5: Sex- and Gender-Unique
 Manifestations of Cardiovascular Disease. CJC Open. 2022;4(3):243-62.
- 752 64. Charlton KE, Corso B, Ware L, Schutte AE, Wepener L, Minicuci N, et al. Effect of
- South Africa's interim mandatory salt reduction programme on urinary sodium excretion andblood pressure. Preventive medicine reports. 2021;23:101469.
- 65. World Health Organization. WHO global sodium benchmarks for different food
 categories. Geneva: WHO;2021. [Available from:
- https://www.who.int/publications/i/item/9789240025097.
- 758 66. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ,
- et al. Projected effect of dietary salt reductions on future cardiovascular disease. New England
- 760 Journal of Medicine. 2010;362(7):590-9.
- 67. Grieger JA, Johnson BJ, Wycherley TP, Golley RK. Evaluation of Simulation Models
 that Estimate the Effect of Dietary Strategies on Nutritional Intake: A Systematic Review. The
 Journal of Nutrition. 2017;147(5):908-31.
- 764 68. Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, et al. Cost
- effectiveness of a government supported policy strategy to decrease sodium intake: globalanalysis across 183 nations. Bmj. 2017;356.
- Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, et al. Low sodium diet
 for gastric cancer prevention in the United States: Results of a Markov model. Cancer Medicine.
 2020.
- 770 70. Kypridemos C, Guzman-Castillo M, Hyseni L, Hickey GL, Bandosz P, Buchan I, et al.
- Estimated reductions in cardiovascular and gastric cancer disease burden through salt policies in
- England: an IMPACTNCD microsimulation study. BMJ open. 2017;7(1):e013791.
- 773 71. Park H-K, Lee Y, Kang B-W, Kwon K-i, Kim J-W, Kwon O-S, et al. Progress on sodium
 774 reduction in South Korea. BMJ Global Health. 2020;5(5):e002028.
- 775 72. Arcand J, Campbell NR. Dietary sodium reduction in Canada: more action is needed to 776 reach the 2025 global targets. CMAJ. 2022;194(10):E387-E8.
- 777 73. Greer RC, Marklund M, Anderson CA, Cobb LK, Dalcin AT, Henry M, et al. Potassium-
- enriched salt substitutes as a means to lower blood pressure: benefits and risks. Hypertension.
 2020;75(2):266-74.
- 780